What is a reasonable rate for specific osteoporosis drug therapy in older fragility fracture patients?
| Autor: | Christian Kammerlander, Sebastian Grueninger, Markus Gosch, Hermann-Joef Bail, Ulla Stumpf, S. Wicklein |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Osteoporosis 030209 endocrinology & metabolism Health Services Misuse 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Older patients Risk Factors Internal medicine medicine Secondary Prevention Humans Orthopedics and Sports Medicine In patient Prospective Studies Geriatric Assessment Aged Cholecalciferol Aged 80 and over Fragility fracture Bone Density Conservation Agents business.industry Hip Fractures Fracture treatment medicine.disease Calcium Dietary Hospitalization Orthopedic surgery Life expectancy Female 030101 anatomy & morphology business Osteoporotic Fractures |
| Zdroj: | Archives of osteoporosis. 15(1) |
| ISSN: | 1862-3514 |
| Popis: | Osteoporosis is the most common condition contributing to 95% of fractures in older patients hospitalized for fracture treatment. Despite the significant impact of fragility fractures on patient morbidity and mortality, efforts in optimizing osteoporotic treatment and prevention remain inadequate. In contrast, in patients with limited life expectancy, withholding specific osteoporosis drug treatment appears reasonable. The threshold between under- and overtreatment is still unclear. In 2016, we implemented a fracture liaison service (FLS) for 18 months to improve the quality of osteoporosis care. We collected prospectively the patient’s history, current treatment for osteoporosis, and risk factors for fragility fractures using a standardized protocol. Recommendations for drug therapy are discussed during the interdisciplinary ward round. The primary outcome parameter was a recommendation for specific osteoporosis drug treatment. We included 681 patients (mean age 82.5 years, 502 (73.7%) females). The inclusion criteria were the following: age of 70 years or older, admission to geriatric fracture center between April 2016 and December 2018. Based on our data, specific osteoporosis drug therapy was recommended in 467 (68.6%) patients. Six hundred fifty-one (95.6%) patients received vitamin D3, and 546 (80.2%) calcium. After adjustment, only age (every 5 years, OR 0.57; 95% CI 0.45–0.72; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink